Global Ophthalmic Drug Market Forecast to Hit $60 Billion by 2031

The sector's growth is fueled by a confluence of demographic shifts and clinical advancements. As life expectancy increases, the prevalence of conditions such as glaucoma, dry eye disease, and age-related macular degeneration has intensified, creating a sustained requirement for specialized medical interventions. Beyond aging, modern lifestyle factors—including prolonged screen exposure and urban environmental stressors—are broadening the patient base, compelling pharmaceutical developers to prioritize both efficacy and patient convenience.

Strategic investment is currently concentrated on drug delivery innovation, with manufacturers shifting toward sustained-release formulations and targeted biologics to improve adherence. North America continues to lead the market share, benefiting from robust research infrastructure and early adoption of innovative treatments. Meanwhile, the Asia-Pacific region is emerging as a critical growth engine, driven by rising healthcare expenditures and expanded access to ophthalmic care in nations like China, India, and Japan. Industry leaders, including Novartis AG, Regeneron Pharmaceuticals, and F. Hoffmann-La Roche AG, are actively competing to capture this demand through aggressive clinical development programs and new product launches.